Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC)..
Because of its key role in cancer development and progression, STAT3 has become an attractive target for developing new cancer therapeutics. While several STAT3 inhibitors have progressed to advanced stages of development, their underlying biology and mechanisms of action are often more complex than would be expected from specific binding to STAT3. Here, we have identified and optimized a series of compounds that block STAT3-dependent luciferase expression with nanomolar potency. Unexpectedly, our lead compounds did not bind to cellular STAT3 but to another prominent anticancer drug target, TrxR1. We further identified that TrxR1 inhibition induced Prx2 and STAT3 oxidation, which subsequently blocked STAT3-dependent transcription. Moreover, previously identified inhibitors of STAT3 were also found to inhibit TrxR1, and likewise, established TrxR1 inhibitors block STAT3-dependent transcriptional activity. These results provide new insights into the complexities of STAT3 redox regulation while highlighting a novel mechanism to block aberrant STAT3 signaling in cancer cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Science advances - 6(2020), 12 vom: 03. März, Seite eaax7945 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Busker, S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.11.2020 Date Revised 25.11.2020 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.aax7945 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308049721 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308049721 | ||
| 003 | DE-627 | ||
| 005 | 20231225130913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.aax7945 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM308049721 | ||
| 035 | |a (NLM)32219156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Busker, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2020 | ||
| 500 | |a Date Revised 25.11.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). | ||
| 520 | |a Because of its key role in cancer development and progression, STAT3 has become an attractive target for developing new cancer therapeutics. While several STAT3 inhibitors have progressed to advanced stages of development, their underlying biology and mechanisms of action are often more complex than would be expected from specific binding to STAT3. Here, we have identified and optimized a series of compounds that block STAT3-dependent luciferase expression with nanomolar potency. Unexpectedly, our lead compounds did not bind to cellular STAT3 but to another prominent anticancer drug target, TrxR1. We further identified that TrxR1 inhibition induced Prx2 and STAT3 oxidation, which subsequently blocked STAT3-dependent transcription. Moreover, previously identified inhibitors of STAT3 were also found to inhibit TrxR1, and likewise, established TrxR1 inhibitors block STAT3-dependent transcriptional activity. These results provide new insights into the complexities of STAT3 redox regulation while highlighting a novel mechanism to block aberrant STAT3 signaling in cancer cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a NF-E2-Related Factor 2 |2 NLM | |
| 650 | 7 | |a NFE2L2 protein, human |2 NLM | |
| 650 | 7 | |a STAT3 Transcription Factor |2 NLM | |
| 650 | 7 | |a STAT3 protein, human |2 NLM | |
| 650 | 7 | |a TXNRD1 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.8.1.9 |2 NLM | |
| 650 | 7 | |a Thioredoxin Reductase 1 |2 NLM | |
| 650 | 7 | |a EC 1.8.1.9 |2 NLM | |
| 700 | 1 | |a Qian, W |e verfasserin |4 aut | |
| 700 | 1 | |a Haraldsson, M |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa, B |e verfasserin |4 aut | |
| 700 | 1 | |a Johansson, L |e verfasserin |4 aut | |
| 700 | 1 | |a Attarha, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kolosenko, I |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, J |e verfasserin |4 aut | |
| 700 | 1 | |a Dagnell, M |e verfasserin |4 aut | |
| 700 | 1 | |a Grandér, D |e verfasserin |4 aut | |
| 700 | 1 | |a Arnér, E S J |e verfasserin |4 aut | |
| 700 | 1 | |a Tamm, K Pokrovskaja |e verfasserin |4 aut | |
| 700 | 1 | |a Page, B D G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 6(2020), 12 vom: 03. März, Seite eaax7945 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:12 |g day:03 |g month:03 |g pages:eaax7945 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.aax7945 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 12 |b 03 |c 03 |h eaax7945 | ||